Adalimumab

Generic Name
Adalimumab
Brand Names
Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
Drug Type
Biotech
Chemical Formula
-
CAS Number
331731-18-1
Unique Ingredient Identifier
FYS6T7F842
Background

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...

Indication

Adalimumab is indicated for the following conditions:

Adalimumab has also been used off-label to treat Pyoderma gangrenosum.

Associated Conditions
Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
Associated Therapies
-
Clinical Trials
Related News

Diabetes Islet Preservation Immune Treatment

First Posted Date
2015-10-26
Last Posted Date
2024-06-06
Lead Sponsor
Camillo Ricordi and Jay Skyler
Registration Number
NCT02586831
Locations
🇺🇸

Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

First Posted Date
2015-09-23
Last Posted Date
2020-09-03
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
80
Registration Number
NCT02557100
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

🇲🇽

Clinica de Investigacion en Reumatologia y Obesidad S.C., Guadalajara, Jalisco, Mexico

🇲🇽

Clinica Integral en Osteoporosis y Artritis CLINOSAR Mexico S.A. de C.V., Mexico D.F., Mexico

and more 24 locations

Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

Not Applicable
Completed
Conditions
Crohn Disease
Interventions
Dietary Supplement: FOS
Drug: Adalimumab
First Posted Date
2015-09-03
Last Posted Date
2018-01-31
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
38
Registration Number
NCT02539849
Locations
🇪🇸

Hospital La Princesa, Madrid, Spain

🇪🇸

Hospital de Bellvitge, Hospitalet del Llobregat, Barcelona, Spain

🇪🇸

Hospital de Santiago, Santiago de Compostela, A Coruña, Spain

and more 2 locations

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

First Posted Date
2015-08-26
Last Posted Date
2019-01-14
Lead Sponsor
AbbVie
Target Recruit Count
10
Registration Number
NCT02533375

A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers

Phase 1
Withdrawn
Conditions
Anaplastic Thyroid Cancers
Interventions
Drug: Adalimumab
First Posted Date
2015-08-06
Last Posted Date
2016-01-26
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Registration Number
NCT02516774
Locations
🇫🇷

Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

First Posted Date
2015-07-14
Last Posted Date
2020-01-28
Lead Sponsor
Takeda
Target Recruit Count
771
Registration Number
NCT02497469
Locations
🇺🇸

Chevy Chase Clinical Research, Chevy Chase, Maryland, United States

🇺🇸

Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

and more 326 locations

Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients

Phase 4
Completed
Conditions
Ankylosing Spondylitis
Interventions
Drug: Adalimumab
First Posted Date
2015-07-08
Last Posted Date
2020-11-03
Lead Sponsor
Universidade Nova de Lisboa
Target Recruit Count
69
Registration Number
NCT02492217
Locations
🇵🇹

Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

Phase 3
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: CHS-1420
Drug: Adalimumab
First Posted Date
2015-07-02
Last Posted Date
2020-04-08
Lead Sponsor
Coherus Biosciences, Inc.
Target Recruit Count
545
Registration Number
NCT02489227
Locations
🇵🇱

Centrum Badań Kliniccznych, Gdańsk, Poland

🇵🇱

Niepubliczny Zaklad Opieki Zdrowtnej "NASZ LEKARZ", Toruń, Poland

🇿🇦

Medicross Pretoria West 1st Floor, Pretoria West, Pretoria, South Africa

and more 94 locations

Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study

Completed
Conditions
Crohn's Disease
Interventions
Drug: Adalimumab
First Posted Date
2015-05-21
Last Posted Date
2024-07-10
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Target Recruit Count
30
Registration Number
NCT02450513
Locations
🇧🇪

University Hospitals Leuven, Leuven, Belgium

🇧🇪

AZ Delta, Roeselare, Belgium

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

First Posted Date
2015-05-07
Last Posted Date
2017-09-15
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
2
Registration Number
NCT02437253
Locations
🇺🇸

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy